Skip to content

Effect of Sijunzi Decoction on expression of blood LYM HLA-DR CD4+/CD8+ and clinical efficacy in patients with sepsis (acute deficiency syndrome)

Effect of Sijunzi Decoction on expression of blood LYM HLA-DR CD4+/CD8+ and clinical efficacy in patients with sepsis (acute deficiency syndrome)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000208
Enrollment
Unknown
Registered
2025-01-28
Start date
2024-03-14
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Conventional treatment Group:Basic treatment of sepsis
Sijunzi decoction Group:Sijunzi decoction is fed orally or nasally

Sponsors

Yancheng TCM Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 95 Years

Inclusion criteria

Inclusion criteria: (1) The Sepsis3.0 diagnostic criteria for sepsis jointly issued by the American Society of Critical Care Medicine and the European Society of Critical Care Medicine in 2016 were met and immunosuppression was present namely LYM < 1.0×109/L; (2) In 2013 Expert Consensus on Diagnosis and Treatment of Sepsis in Combination of traditional Chinese and Western Medicine and the dialectical treatment principle of "four syndroms and four methods" in combination of traditional Chinese and Western medicine proposed by Professor Wang Jida's team were deficiency syndrome.

Exclusion criteria

Exclusion criteria: (1) Patients who have used hormones immunosuppressants or other immune stimulants in the past 1 month; (2) Terminal stage of malignant tumor; (3) A history of liver lung kidney bone marrow transplantation; (4) Women during pregnancy; (5) There are patients who are contraindicated to take TCM decoction; (6) Patients and family members unanimously give up active rescue take the initiative to withdraw or lost visitors.

Design outcomes

Primary

MeasureTime frame
Lymphocyte count;

Secondary

MeasureTime frame
Evaluation of curative effect of TCM syndrome;NK;The maximum dose of vasoactive drugs applied;GCS;CD3+;IL-6;SOFA;IgG;Blood purification time;CRP;CD4+/CD8+;TCM syndrome integral;Fluid infusion in 24 hours;28-day survival;WBC;Vasoactive drug application time;IgM;PCT;Length of ICU stay;HLA-DR;APACHE?;Lac;90-day survival;Mechanical ventilation time;

Countries

China

Contacts

Public ContactGongjie

Yancheng TCM Hospital

981276531@qq.com15951835079

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026